As an accomplished patient-focused biotech executive, my mission is to address serious unmet medical needs by developing innovative therapeutics, and to generate compelling, patient-centric evidence with urgency. I build and lead high-performing teams through authenticity, collaboration and respect, and by fostering an open, energetic, creative and results-driven culture towards great strategy and execution.My expertise includes fit-for-purpose approaches to drug development, operational effectiveness, regulatory excellence, and productive alliances and partnerships. I developed numerous successful therapeutics across modalities including innovative small molecules, biologics, mAbs, oligonucleotides, and antibody-oligonucleotide conjugates. My experience spans INDs/CTAs and all phases in drug development through NDA/MAA filing in rare, orphan and non-rare, prevalent diseases. I have authored over 30 peer-reviewed articles published in journals such as: Science, Cell, NEJM, Nature Genetics, Lancet, JCI, JAMA.Accreditations: Fellow of the American College of Cardiology, 2008 | Diplomate in Cardiovascular Disease, American Board of Internal Medicine, 2007 | Diplomate in Internal Medicine, American Board of Internal Medicine, 2000